ELIGARD (leuprolide acetate) for injectable suspension logo
ELIGARD (leuprolide acetate) for injectable suspension logo
  • Important Safety Information
  • Full Prescribing Information
  • Patient Site
  • Contact
  • Important Safety Information
  • Full Prescribing Information
  • Patient Site
  • Contact
Eligard Information Center
  • Proven
    Efficacy & Safety
    • Established reputation
    • Profound T suppression
    • Low T breakthrough occurrences
    • Importance of nadir T
    • Well-established safety
  • Customizable
    Dosing
  • Extended
    Control
    • Extended delivery system
    • EPSS
    • Mixing & Administration
    • Storage
  • Unmatched
    support & access
    • Ordering
    • TOLMARsync
    • Prostate Cancer 360
    • More support
    • For your patients
    • Financial toxicity
  • Sign
    up
  • Proven
    Efficacy & Safety
    • Established reputation
    • Profound T suppression
    • Low T breakthrough occurrences
    • Importance of nadir T
    • Well-established safety
  • Customizable
    Dosing
  • Extended
    Control
    • Extended delivery system
    • EPSS
    • Mixing & Administration
    • Storage
  • Unmatched
    support & access
    • Ordering
    • TOLMARsync
    • Prostate Cancer 360
    • More support
    • For your patients
    • Financial toxicity
  • Sign
    up

CONTACT

Adverse event reporting

To report an adverse event, please call ​1​-​8​8​8​-ELIG​ARD

Customer service

To place an order or contact customer service for ELIGARD®, call ​1-​877-​ELIGARD

Comments or questions?

Tolmar welcomes your feedback and queries. Please contact US Sales and Marketing at:
  • 485 Half Day Road, Suite 400
    Buffalo Grove, IL 60089
  • ​1-​844​-4TOLMAR (​1-844​-4​8​6​-5​6​2​7)
  • info@tolmar.com
Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.
ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Steve-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.
ELIGARD may impair fertility in males of reproductive potential.
The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.
Please see full Prescribing Information for ELIGARD.
tolmar-logo
©2024 Tolmar, Inc. All rights reserved. Tolmar, ELIGARD, TOLMARsync, Tolmar Total Solutions, and their associated logos are trademarks of the Tolmar group. Third-party trademarks, product names, and copyrights belong to their respective owners.
TPI.2024.eng.4323.v2 4/25
This site is intended for use by US residents only.

CORPORATE OFFICES

485 Half Day Road,
Suite 400
Buffalo Grove, IL 60089

1-224-880-5770

info@tolmar.com

  • Privacy Policy
  • Site Map
  • Terms & Conditions
  • Tolmar
  • Proven
    Efficacy & Safety
    • Established reputation
    • Profound T suppression
    • Low T breakthrough occurrences
    • Importance of nadir T
    • Well-established safety
  • Customizable
    Dosing
  • Extended
    Control
    • Extended delivery system
    • EPSS
    • Mixing & Administration
    • Storage
  • Unmatched
    support & access
    • Ordering
    • TOLMARsync
    • Prostate Cancer 360
    • More support
    • For your patients
    • Financial toxicity
  • Sign
    up
  • Important Safety Information
  • Full Prescribing Information
  • Patient Site
  • Contact

You are now leaving
ELIGARDhcp.COM

Are you sure you want to leave? 

continue to site
cancel
Skip to content